ORLANDO, Fla., September 6, 2011 – All cells need glucose (sugar) to produce the energy they need to survive. High glucose levels in the bloodstream (such as occur after a meal), trigger the pancreas to produce insulin. In turn, muscle and fat cells respond to insulin by moving GLUT4, a glucose transporter, from intracellular storage out to the cell surface. There, GLUT4 can take up the glucose the cell needs from the bloodstream. Now, a new study led by Zhen Y. Jiang, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) identifies the protein—called CDP138—responsible for ensuring that GLUT4 is properly inserted in the cellular membrane. These results, appearing September 7 in Cell Metabolism, provide a new understanding of glucose metabolism—an important finding considering that impaired insulin action and glucose metabolism contribute to the development of type 2 diabetes.
"This is a newly identified protein that's involved in an important step in glucose uptake," said Dr. Jiang, assistant professor in Sanford-Burnham's Diabetes and Obesity Research Center, located in Orlando's Medical City at Lake Nona.
There are two main steps that get GLUT4 from intracellular storage to the cell surface in fat and muscle tissue. First, a vesicle containing the stored transporter moves to (and docks at) the outer membrane. Second, GLUT4 from the docked vesicle inserts into the membrane. Insulin triggers this process and a protein pathway spearheaded by a protein called Akt2 is known to initiate both steps.
In this study, the research team set out to determine how the cell specifically controls that final step—fusion of the glucose storage vesicles and the cell's outer membrane. To do this, they went looking for Akt2 substrates—other proteins that Akt2 acts upon. Through phosphoproteomics and RNA interference (RNAi)-based functional analyses, they came upon a protein they called CDP138. Then, to pinpoint its exact function, they genetically dampened CDP138 in live fat cells. As a result, the researchers found that this previously unknown protein is required for optimal insulin-stimulated GLUT4 transport to the cell surface and fusion of GLUT4-containing vesicles with the membrane. Through these functions, CDP138 was also required for glucose transport in live fat cells. Drilling deeper, the team also identified the exact part of the CDP138 protein that is chemically modified by Akt2 and showed that, without that region, CDP138 was unable to carry out its function.
It's possible that CD138 contributes to diabetes in humans. Preliminary experiments suggest that mice engineered to be obese have lower CD138 levels than normal mice. It remains to be seen whether this is the case in humans and whether CD138's correlation with obesity is a cause of obesity or an effect—or simply a correlation.
"We are now generating a mouse model that lacks CD138," Dr. Jiang said. "Over the next year, we'll be looking to see if these mice experience changes in their glucose metabolism in response to insulin and exercise."
The authors of this study are Xiangyang Xie, Zhenwei Gong, Virginie Mansuy-Aubert, Daniel Sehrt, Laurence M. Brill, Khatereh Motamedchaboki and Zhen Y. Jiang from Sanford-Burnham, Qiong L. Zhou and Michael P. Czech from the University of Massachusetts Medical School, Suren A. Tatulian from the University of Central Florida, Florian Gnad, Matthias Mann and Marcus KrÜger from the Max-Planck Institute and Yu Chen from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) at the NIH.
For more information about Sanford-Burnham research, visit our blog (http://beaker.sanfordburnham.org) or follow us on Twitter (http://twitter.com/SanfordBurnham).
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The Institute ranks among the top independent research institutions nationally for NIH grant funding and among the top organizations worldwide for its research impact. From 1999 – 2009, Sanford-Burnham ranked #1 worldwide among all types of organizations in the fields of biology and biochemistry for the impact of its research publications, defined by citations per publication, according to the Institute for Scientific Information. According to government statistics, Sanford-Burnham ranks #2 nationally among all organizations in capital efficiency of generating patents, defined by the number of patents issued per grant dollars awarded.
Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a nonprofit public benefit corporation. For more information, please visit www.sanfordburnham.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.